Vivoryon Therapeutics N.V. (0R3M.L) LSE
1.16
-0.05(-4.13%)
Currency In EUR
- General
- Statistics
- Historical Data
- Profile
- Financials
1.16
-0.05(-4.13%)
Currency In EUR
Sector
Healthcare
Industry
Biotechnology
Employees
14
First IPO Date
April 23, 2015
| Name | Title | Pay | Year Born |
| Frank T. Weber | MD, CEO, Chief Medical Officer & Executive Director | 329,000 | 1960 |
| Marcus Irsfeld | Chief Financial Officer & Executive Director | 109,000 | 1966 |
| Konrad Glund | Co-Founder & Advisor | 222,113 | 1953 |
| Julia Neugebauer | Head of Investor Relations & Communications, COO & Executive Board Member | 259,000 | 1979 |
| Hendrik Liebers | Advisor | 319,196 | 1971 |
| Michael Schaeffer | Chief Business Officer & Executive Director | 341,000 | 1969 |
| Manuela Bader | Director of Investor Relations & Communications | 0 | N/A |
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease; and for the treatment of cancer. Its preclinical development product is PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor for the treatment of cancer. In addition, the company is developing a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Vivoryon Therapeutics N.V. has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.